Abstract
Recombinant DNA technology has provided invaluable tools for understanding the molecular basis of cardiovascular diseases. Elucidation of the underlying molecular genetic mechanisms of cardiovascular disease has led to the emergence of gene therapy as an appealing therapeutic approach. Gene therapy involves the introduction and expression of recombinant DNA in order to ameliorate or cure a disease condition. Despite the extensive publicity devoted to gene therapy, it must be emphasized that this field is still very much in its infancy, and fundamental questions regarding efficacy, safety, and clinical benefit remain unanswered. Initial clinical trials in cardiovascular gene therapy are at an early stage, and the place of gene therapy within the armamentarium of cardiovascular therapeutics remains uncertain. This chapter is devoted principally to a review of the theoretical basis for cardiovascular gene therapy, as established by in vitro and preclinical animal experiments. In addition, the two currently approved human cardiovascular gene-therapy trials (familial hypercholesterolemia [FH; MIM # 14389] and peripheral arterial disease) are discussed, and the likely future directions of the field are summarized.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected References
Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders using a constitutively active form of RB. Science 1995; 267: 518–522.
Clowes MM, Lynch CM, Miller AD, Miller DG, Osborne WR, Clowes AW. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. J Clin Invest 1994; 93: 644–651.
Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301–309.
Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11, 421–11, 425.
Flugelman MY, Jaklitsch MT, Newman KD, et al. Low level in vivo gene transfer into the arterial wall through a perforated balloon-catheter. Circulation 1992; 85: 1110–1117.
Grossman M, Rader DJ, Muller DWM, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148–1154.
Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812–2816.
Isner JM, Walsh K, Symes J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995; 91: 2687–2692.
Kopfler WP, Willard M, Betz T, Willard JE, Gerard JE, Meidell RS. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation 1994; 90: 1319–1327.
Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 1995; 1129–1144.
Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73: 797–807.
Nabel EG, Plautz G, Nabel GJ. Site-specific gene-expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285–1288.
Nabel E. Gene therapy for cardiovascular disease. Circulation 1995; 91: 541–547.
Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955–2965.
O’Brien ER, Schwartz SM. Update on the biology and clinical study of restenosis. Trends Cardiovasc Med 1994; 4: 169–178.
Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781–784.
Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996; 2: 293–298.
Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity. Circulation 1995; 91: 2407–2414.
Spady DK, Cuthbert JA, Willard MN, Meidell RS. Adenovirus-mediated transfer of a gene encoding cholesterol 7a-hydroxylase into hamsters increases hepatic enzyme activity and reduces plasma total and low density lipoprotein cholesterol. J Clin Invest 1995; 96: 700–709.
von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137–1141.
Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995; 95: 1710–1716.
Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004–2115.
Zoldhelyi P, McNatt J, Xu X-M, et al. Prevention of arterial thrombosis by adenovirus-mediated gene transfer of cyclooxygenase gene. Circulation 1996; 93: 10–17.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vassalli, G., Dichek, D.A. (1998). Cardiovascular Gene Therapy. In: Jameson, J.L. (eds) Principles of Molecular Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-726-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-59259-726-0_18
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6272-3
Online ISBN: 978-1-59259-726-0
eBook Packages: Springer Book Archive